ClinicalTrials.gg
CompletedNCT01551212HEPHAISTOSUpdated May 10, 2019Results posted

Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients

A Phase 4 interventional study of Everolimus and Tacrolimus in Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
339
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This trial evaluated the efficacy and safety of Everolimus in combination with tacrolimus versus a standard immunosuppressive regimen concerning kidney function in liver transplant recipients.

02

Conditions studied

  • Liver Transplantation

Keywords

  • Liver transplantation
  • Everolimus
  • Tacrolimus
  • Renal function
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female recipients of a full-size liver allograft, aged 18 to 65 years.

Exclusion criteria

Exclusion criteria:

Patients with thrombocytopenia ( \<50,000/mm³), with an of \<1,000/mm³ or leucopenia (leucocytes \<2000/mm³), with anemia with \< 6g/dl at time of randomization

Patients with uncontrolled hypercholesterolemia (>350mg/dL; >9mmol/L) or hypertriglyceridemia (>750 mg/dL; >8.5 mmol/L) at time of randomization

History of of any organ system within the past 5 years whether or not there is evidence of local recurrence or , other than non-metastatic basal or squamous cell carcinoma of the skin or HCC

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
339 participants (actual)

Study arms

  • Experimental
    EVR/TAC

    Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: \< 5 ng/mL)

    Drug: Everolimus · Drug: Tacrolimus · Drug: Corticosteroids

  • Active comparator
    TAC

    Tacrolimus (C0-h: 6-10 ng/ml)

    Drug: Tacrolimus · Drug: Corticosteroids

Interventions

  • tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg

    Also known as: RAD001 / Certican

  • capsule containing 0.5, 1.0, or 5.0mg

    Also known as: Tacrolimus Hexal

  • DrugCorticosteroids

    For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.

06

What researchers measure

Primary outcomes

  1. Estimated Glomerular Filtration Rate (GFR)

    The estmated GFR was calculated using MDRD-4 formula (Modification of Diet in Renal Disease Study Group).

    Time frame: month 12

Secondary outcomes

  1. Estimated GFR - PP Set

    This was a sensitivity analysis for the primary outcome measure based on the per-protocol set of patients.

    Time frame: month 12

  2. Percentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death

    Percentage of Participants with Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death at Month 12

    Time frame: 12 months

  3. Number of Participants With HCV

    Number of Participants with HCV (hepatitis C virus) assessed as treatment emergent adverse events of special interest

    Time frame: 12 months

  4. Incidence of HCV Related Fibrosis

    Incidence of hepatitis C virus (HCV) related fibrosis assessed as treatment emergent adverse events of special interest

    Time frame: 12 months

  5. Incidence of de Novo HCC Malignancies

    Incidence of de novo Hepatocellular Carcinoma (HCC) malignancies assessed as treatment emergent adverse events of special interest

    Time frame: 12 months

  6. Incidence and Severity of CMV Viral Infections.

    Incidence and severity of cytomegalovirus (CMV) viral infections assessed as treatment emergent adverse events of special interest.

    Time frame: 12 months

07

Results

Posted May 10, 2019

Participant flow

In total, 642 patients were screened for study eligibility at 15 study centers in Germany. 339 patients were randomized out of which 333 received study treatment and were included in the analyses.

Participant flow — Overall Study
MilestoneEverolimus/TacrolimusTacrolimus
Started171168
Full anylsis set (fas)169164
Safety set169164
Per protocol set (pp)110101
Completed166148
Not completed520
Withdrew: Graft loss/retransplantation01
Withdrew: Administrative problems12
Withdrew: Lost to follow-up01
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject07
Withdrew: Death24
Withdrew: Never received study treatment24

Outcome measures

PrimaryEstimated Glomerular Filtration Rate (GFR)

The estmated GFR was calculated using MDRD-4 formula (Modification of Diet in Renal Disease Study Group).

Time frame:
month 12
Reported as:
Mean · mL/min
Estimated Glomerular Filtration Rate (GFR)
mL/minEverolimus/TacrolimusTacrolimus
Estimated Glomerular Filtration Rate (GFR)73.46 ± 25.5771.95 ± 27.17
Statistical analysis
  • Everolimus/Tacrolimus vs Tacrolimus · ANCOVA · p = 0.097 · Mean difference (final values): 4.09 · 95% CI -0.74 to 8.91factors: treatment, center, HCV-Class (positive, negative) and lab MELD (≤ 30 vs \> 30) covariate: baseline value
SecondaryEstimated GFR - PP Set

This was a sensitivity analysis for the primary outcome measure based on the per-protocol set of patients.

Time frame:
month 12
Reported as:
Mean · mL/min
Estimated GFR - PP Set
mL/minEverolimus/TacrolimusTacrolimus
Estimated GFR - PP Set74.83 ± 25.1970.65 ± 24.91
Statistical analysis
  • Everolimus/Tacrolimus vs Tacrolimus · ANCOVA · p = 0.0085 · Mean difference (final values): 7.99 · 95% CI 2.06 to 13.92factors: treatment, center, HCV-Class (positive, negative) and lab MELD (≤ 30 vs \> 30) covariate: baseline value
SecondaryPercentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death

Percentage of Participants with Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death at Month 12

Time frame:
12 months
Reported as:
Number · Percent of Patients
Percentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death
Percent of PatientsEverolimus/TacrolimusTacrolimus
Percentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death9.57.9
Statistical analysis
  • Everolimus/Tacrolimus vs Tacrolimus · Fisher Exact · p = 0.699
SecondaryNumber of Participants With HCV

Number of Participants with HCV (hepatitis C virus) assessed as treatment emergent adverse events of special interest

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With HCV
ParticipantsEverolimus/TacrolimusTacrolimus
Number of Participants With HCV612
SecondaryIncidence of HCV Related Fibrosis

Incidence of hepatitis C virus (HCV) related fibrosis assessed as treatment emergent adverse events of special interest

Time frame:
12 months
Reported as:
Count of participants · Participants
Incidence of HCV Related Fibrosis
ParticipantsEverolimus/TacrolimusTacrolimus
Incidence of HCV Related Fibrosis10
SecondaryIncidence of de Novo HCC Malignancies

Incidence of de novo Hepatocellular Carcinoma (HCC) malignancies assessed as treatment emergent adverse events of special interest

Time frame:
12 months
Reported as:
Count of participants · Participants
Incidence of de Novo HCC Malignancies
ParticipantsEverolimus/TacrolimusTacrolimus
Incidence of de Novo HCC Malignancies02
SecondaryIncidence and Severity of CMV Viral Infections.

Incidence and severity of cytomegalovirus (CMV) viral infections assessed as treatment emergent adverse events of special interest.

Time frame:
12 months
Reported as:
Count of participants · Participants
Incidence and Severity of CMV Viral Infections.
ParticipantsEverolimus/TacrolimusTacrolimus
No CMV viral infection136129
Asymptomatic05
Mild1620
Moderate139
Severe41

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus/Tacrolimus3/169 (1.8%)111/169 (65.7%)164/169 (97%)
Tacrolimus4/164 (2.4%)101/164 (61.6%)153/164 (93.3%)
Most frequent serious events
Showing 10 of 272
Most frequent serious events
EventEverolimus/TacrolimusTacrolimus
BILIARY ANASTOMOSIS COMPLICATIONInjury, poisoning and procedural complications8/16913/164
CHOLANGITISHepatobiliary disorders13/1697/164
LIVER TRANSPLANT REJECTIONImmune system disorders12/1699/164
INCISIONAL HERNIAInjury, poisoning and procedural complications11/1694/164
PNEUMONIAInfections and infestations10/1697/164
ACUTE KIDNEY INJURYRenal and urinary disorders10/1698/164
HEPATIC ENZYME INCREASEDInvestigations6/1697/164
BILE DUCT STENOSISHepatobiliary disorders5/1696/164
TRANSAMINASES INCREASEDInvestigations2/1696/164
CHOLANGITIS INFECTIVEInfections and infestations6/1691/164
Most frequent other events
Showing 10 of 54
Most frequent other events
EventEverolimus/TacrolimusTacrolimus
HEADACHENervous system disorders48/16922/164
LEUKOPENIABlood and lymphatic system disorders45/16912/164
DIARRHOEAGastrointestinal disorders43/16939/164
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations41/16929/164
OEDEMA PERIPHERALGeneral disorders38/16915/164
INCISIONAL HERNIAInjury, poisoning and procedural complications35/16910/164
URINARY TRACT INFECTIONInfections and infestations30/16924/164
HYPERCHOLESTEROLAEMIAMetabolism and nutrition disorders30/1699/164
CYTOMEGALOVIRUS INFECTIONInfections and infestations24/16928/164
HYPERTENSIONVascular disorders28/16924/164

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Everolimus/TacrolimusTacrolimusTotal
Mean53.68 ± 9.3853.46 ± 9.6453.57 ± 9.49
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus/TacrolimusTacrolimusTotal
Female364379
Male133121254
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus/TacrolimusTacrolimusTotal
Caucasian168157325
Black112
Asian033
Other033
08

Study locations

15 sites
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Erlangen, 91052, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Munchen, 81377, Germany
  • Novartis Investigative Site
    Regensburg, 93053, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
09

References and documents

Publications

  • Nashan B, Schemmer P, Braun F, Schlitt HJ, Pascher A, Klein CG, Neumann UP, Kroeger I, Wimmer P; Hephaistos Study Group. Early Everolimus-Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial. Liver Transpl. 2022 Jun;28(6):998-1010. doi: 10.1002/lt.26298. Epub 2021 Oct 12. PubMed 34525259 ↗
  • Nashan B, Schemmer P, Braun F, Dworak M, Wimmer P, Schlitt H. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. Trials. 2015 Mar 26;16:118. doi: 10.1186/s13063-015-0626-0. PubMed 25873064 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2012 to primary completion in Aug 2017, 62 months.

Results were first posted in May 2019, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2012
First posted
Mar 12, 2012
StartActual
May 24, 2012
Primary completionActual
Aug 8, 2017
CompletionActual
Aug 8, 2017
Results first posted
May 10, 2019
Last update
May 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01551212
Responsible party
Sponsor
First posted
Mar 12, 2012
Start date
May 24, 2012
Primary completion
Aug 8, 2017
Completion
Aug 8, 2017
Results posted
May 10, 2019
Last update
May 10, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion